Search results for "Imipenem"

showing 10 items of 20 documents

Epidemiology and clonality of carbapenem-resistant Acinetobacter baumannii from an intensive care unit in Palermo, Italy

2012

Abstract Background Multidrug-resistant Acinetobacter baumannii, initially considered as having a poor clinical relevance, is frequently isolated from infection cases in intensive care units. We describe the epidemiology of carbapenem resistant A. baumannii (CRAB) in a general ICU in Palermo, Italy, from October 2010 to March 2011. Findings 58 of 61 isolates exhibited MICs for meropenem or imipenem ≥16 mg/L. Forty-nine carried blaOXA-23 and two blaOXA-58 genes. Five subtype clusters were detected by rep-PCR. Clusters D and E included 10 isolates that tested negative for the carbapenem resistance genes. MLST attributed all isolates, but two, with sequence type (ST)2, whereas the two remainin…

MaleAcinetobacter baumanniiImipenemSettore MED/07 - Microbiologia E Microbiologia ClinicaTime Factorslcsh:MedicineTigecyclinePolymerase Chain Reactionintensive care unitlaw.inventionlawDrug Resistance Multiple BacterialEpidemiologypolycyclic compoundsMedicinelcsh:QH301-705.5Medicine(all)Aged 80 and overbiologyGeneral MedicineMiddle AgedIntensive care unitAcinetobacter baumanniiIntensive Care UnitsItalyFemaleAcinetobacter baumannii; intensive care unitAcinetobacter Infectionsmedicine.drugAdultmedicine.medical_specialtyAdolescentShort ReportMicrobial Sensitivity TestsMeropenemGeneral Biochemistry Genetics and Molecular BiologyYoung AdultIntensive careHumansIntensive care medicinelcsh:Science (General)AgedDemographyBiochemistry Genetics and Molecular Biology(all)business.industrylcsh:Rbiochemical phenomena metabolism and nutritionbacterial infections and mycosesbiology.organism_classificationClone CellsCarbapenemslcsh:Biology (General)bacteriabusinessCarbapenem resistant Acinetobacter baumanniilcsh:Q1-390BMC Research Notes
researchProduct

Nosocomial colonization due to imipenem-resistant Pseudomonas aeruginosa epidemiologically linked to breast milk feeding in a neonatal intensive care…

2008

Aim: We describe a one-year investigation of colonization by imipenemresistant, metallo-β-lactamase (MBL) producing Pseudomonas aeruginosa in a neonatal intensive care unit (NICU) of the University Hospital of Palermo, Italy. Methods: A prospective epidemiological investigation was conducted in the period 2003 January to 2004 January. Rectal swabs were collected twice a week from all neonates throughout their NICU stay. MBL production by imipenem-resistant strains of P aeruginosa was detected by phenotypic and molecular methods. Pulsed field gel electrophoresis (PFGE) was carried out on all isolates of P aeruginosa. The association between risk factors and colonization by imipenem-resistant…

Malemedicine.medical_specialtyImipenemNeonatal intensive care unitSettore MED/17 - Malattie Infettivemetallo-β-lactamaseDrug resistanceMicrobial Sensitivity TestsBreast milkmedicine.disease_causeMicrobiologyRisk FactorsDrug Resistance Multiple BacterialIntensive Care Units NeonatalEpidemiologymedicinePulsed-field gel electrophoresisHumansPharmacology (medical)ColonizationPseudomonas InfectionsProspective StudiesProportional Hazards ModelsPharmacologyCross InfectionMilk HumanPseudomonas aeruginosabusiness.industryInfant NewbornGeneral Medicinebacterial infections and mycosesneonatal intensive care unitAnti-Bacterial AgentsSurvival RateImipenemBreast FeedingPseudomonas aeruginosabreast milkFemalebusinessmedicine.drugActa pharmacologica Sinica
researchProduct

Sequence type 101 (ST101) as the predominant carbapenem-non-susceptible Klebsiella pneumoniae clone in an acute general hospital in Italy.

2012

Klebsiella pneumoniae is one of the most common multidrug-resistant (MDR) Gram-negative organisms worldwide, responsible for high morbidity and mortality both in hospitals and alternative healthcare settings. Recently, increasing use of carbapenems has promoted the emergence and dissemination of carbapenem-non-susceptible MDR K. pneumoniae strains. All of the CNSKP strains isolated between January 2009 and December 2011 in the General Hospital of Prato (Prato, Italy) were studied. Our findings indicate that, unlike previously reported by other authors from different regions of Italy, K. pneumoniae producing KPC-2 and belonging to ST101 have been established in the area of Prato, Tuscany, It…

Microbiology (medical)CarbapenemSettore MED/07 - Microbiologia E Microbiologia ClinicaKlebsiella pneumoniaeClone (cell biology)Drug resistanceMicrobial Sensitivity TestsSettore MED/42 - Igiene Generale E ApplicataHospitals Generalbeta-LactamsMicrobiologyDrug Resistance BacterialmedicineHumansPharmacology (medical)General hospitalhospitalSequence (medicine)Cross InfectionbiologyGeneral Medicinebiology.organism_classificationST101Anti-Bacterial AgentsKlebsiella InfectionsImipenemKlebsiella pneumoniaeInfectious DiseasesCarbapenemsItalymedicine.drugInternational journal of antimicrobial agents
researchProduct

New β-Lactam-β-Lactamase Inhibitor Combinations.

2020

The limited armamentarium against drug-resistant Gram-negative bacilli has led to the development of several novel β-lactam-β-lactamase inhibitor combinations (BLBLIs). In this review, we summarize their spectrum of in vitro activities, mechanisms of resistance, and pharmacokinetic-pharmacodynamic (PK-PD) characteristics. A summary of available clinical data is provided per drug. Four approved BLBLIs are discussed in detail. All are options for treating multidrug-resistant (MDR) Enterobacterales and Pseudomonas aeruginosa Ceftazidime-avibactam is a potential drug for treating Enterobacterales producing extended-spectrum β-lactamase (ESBL), Klebsiella pneumoniae carbapenemase (KPC), AmpC, an…

Microbiology (medical)DrugImipenemBacilliEpidemiologyKlebsiella pneumoniaemedia_common.quotation_subjectMicrobial Sensitivity Testsmedicine.disease_causebeta-LactamsMeropenemMicrobiologyDrug Resistance Multiple BacterialGram-Negative Bacteriapolycyclic compoundsmedicinemedia_commonGeneral Immunology and MicrobiologybiologyPseudomonas aeruginosabusiness.industryPublic Health Environmental and Occupational Healthbiochemical phenomena metabolism and nutritionbacterial infections and mycosesbiology.organism_classificationCeftazidime/avibactamAcinetobacter baumanniiDrug CombinationsInfectious DiseasesbacteriaErratumbusinessbeta-Lactamase Inhibitorsmedicine.drugClinical microbiology reviews
researchProduct

Comparative clinical trial of ceftazidime and imipenem/cilastatin in patients with severe nosocomial pneumonias and septicaemias.

1990

The efficacy and safety of ceftazidime and imipenem in patients with severe infections was compared in a randomized multi-centre trial. Patients on assisted respiration with clinical signs of pneumonia or septicaemia who had been in hospital for at least 3 days were studied. Twenty-one patients were treated with ceftazidime, 24 with imipenem. The mean duration of treatment was 9 days in both groups. At the end of the trial 17 patients (81%) of the ceftazidime group and 16 patients (67%) in the imipenem group were clinically cured or showed marked improvement. The bacteriological results showed an eradication of the causative pathogens in 17 of 21 cases in the ceftazidime group and 13 of 19 …

Microbiology (medical)Malemedicine.medical_specialtyImipenemCeftazidimeHospital-acquired pneumoniaCeftazidimeInternal medicineSepsismedicineHumansMulticenter Studies as TopicIn patientRandomized Controlled Trials as TopicCross Infectionbusiness.industryImipenem/cilastatinGermany WestGeneral MedicinePneumoniaMiddle Agedbacterial infections and mycosesmedicine.diseaseRespiration ArtificialSurgeryClinical trialPneumoniaDrug CombinationsImipenemInfectious DiseasesCilastatinFemalebusinessmedicine.drugThe Journal of hospital infection
researchProduct

Multiclonal emergence of carbapenem-resistant Klebsiella pneumoniae in Tuscany, Italy

2010

Microbiology (medical)Settore MED/07 - Microbiologia E Microbiologia ClinicaImipenemGenotypemedicine.drug_classCarbapenem resistant Klebsiella pneumoniaemedicine.medical_treatmentAntibioticsMicrobial Sensitivity TestsBiologySettore MED/42 - Igiene Generale E ApplicataMeropenembeta-Lactam Resistancebeta-LactamasesMicrobiologychemistry.chemical_compoundmedicineHumansPharmacology (medical)Molecular EpidemiologyKlebsiella pneumoniae resistenza ai carbapenemi multiclonaleGeneral MedicineDNA FingerprintingAnti-Bacterial AgentsBacterial Typing TechniquesElectrophoresis Gel Pulsed-FieldKlebsiella InfectionsMultiple drug resistanceKlebsiella pneumoniaePhenotypeInfectious DiseasesCarbapenemsItalychemistryBeta-lactamaseErtapenemmedicine.drugBeta lactam antibioticsInternational Journal of Antimicrobial Agents
researchProduct

Meropenem Permeation through the Outer Membrane of <i>Pseudomonas aeruginosa</i> Can Involve Pathways Other than the OprD Porin Channel

1996

The outer membrane protein (OMP) OprD is the major channel through which carbapenems permeate the outer membrane of Pseudomonas aeruginosa. In this study, we analyzed the OMP profiles of several P. aeruginosa clinical isolates showing diminished susceptibility to imipenem while remaining susceptible to meropenem. All these isolates lacked OprD or showed a reduced expression of this porin. Susceptibility to meropenem was thus independent of the level of OprD expression, indicating that the antimicrobial could be taken up via an alternative route. The level of expression of OprC (70 kD) was also unrelated to meropenem susceptibility. Nevertheless, OMPs OprF and OprE were expressed by all isol…

PharmacologyImipenembiologyPseudomonas aeruginosaGeneral Medicinebiochemical phenomena metabolism and nutritionbacterial infections and mycosesbiology.organism_classificationmedicine.disease_causeMeropenemPorinaMicrobiologyInfectious DiseasesOncologyDrug DiscoveryPorinpolycyclic compoundsmedicinebacteriaPharmacology (medical)Bacterial outer membranemedicine.drugPseudomonadaceaeAntibacterial agentChemotherapy
researchProduct

Antibiotic Susceptibility Patterns and Molecular Epidemiology of Metallo-β-Lactamase Producing Pseudomonas Aeruginosa Strains Isolated From Burn Pati…

2014

BACKGROUND: Failure in the treatment of burn patients infected with Pseudomonas aeruginosa could happen as a result of the acquisition of antibiotic resistance, including carbapenems. OBJECTIVES: The aim of the present study was to investigate the phenotypic and genotypic characteristics of the Pseudomonas aeruginosa strains, isolated from burn patients. PATIENTS AND METHODS: During a 12 month period, in this cross-sectional study, two hundred seventy strains of Pseudomonas aeruginosa were isolated from the burn patients in Ghotbeddin Burn Hospital, Shiraz, Iran. Screening for the carbapenem resistance in the isolates was carried out by the E test method. Sensitivity patterns of metallo-β-l…

Settore MED/07 - Microbiologia E Microbiologia ClinicaImipenembiologyBeta-LactamasePseudomonas aeruginosabusiness.industryPseudomonasCeftazidimeMeropenemGeneral Medicinemedicine.disease_causebiology.organism_classificationMeropenemMicrobiologyImipenemAntibiotic resistanceAmikacinmedicinePulsed-field gel electrophoresisBeta-LactamasesbusinessPulsed Field Gel ElectrophoresisResearch Articlemedicine.drugIranian Red Crescent Medical Journal
researchProduct

Mechanisms of Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa : Results of the GERPA Multicenter Study

2020

ABSTRACT Resistance mechanisms of Pseudomonas aeruginosa to ceftolozane/tazobactam (C/T) were assessed on a collection of 420 nonredundant strains nonsusceptible to ceftazidime (MIC > 8 μg/ml) and/or imipenem (>4 μg/ml), collected by 36 French hospital laboratories over a one-month period (the GERPA study). Rates of C/T resistance (MIC > 4/4 μg/ml) were equal to 10% in this population (42/420 strains), and 23.2% (26/112) among the isolates resistant to both ceftazidime and imipenem. A first group of 21 strains (50%) was found to harbor various extended-spectrum β-lactamases (1 OXA-14; 2 OXA-19; 1 OXA-35; 1 GES-9; and 3 PER-1), carbapenemases (2 GES-5; 1 IMP-8; and 8 VIM-2), or both (1 VIM-2…

TazobactamImipenemPopulationCeftazidimeMicrobial Sensitivity TestsBiologymedicine.disease_causeCeftazidimeTazobactambeta-LactamasesMicrobiology03 medical and health sciencesCloxacillinMechanisms of Resistance[CHIM.ANAL]Chemical Sciences/Analytical chemistrymedicineHumans[CHIM]Chemical SciencesPseudomonas InfectionsPharmacology (medical)[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyeducationComputingMilieux_MISCELLANEOUS030304 developmental biologyPharmacology0303 health scienceseducation.field_of_study030306 microbiologyPseudomonas aeruginosabiochemical phenomena metabolism and nutritionAnti-Bacterial AgentsCephalosporins3. Good healthInfectious DiseasesPseudomonas aeruginosaColistinCeftolozanemedicine.drug
researchProduct

Double copies of blaKPC-3::Tn4401a on an IncX3 plasmid in Klebsiella pneumoniae successful clone ST512 from Italy

2015

ABSTRACT A carbapenem-resistant sequence type 512 (ST512) Klebsiella pneumoniae carbapenemase 3 (KPC-3)-producing K. pneumoniae strain showing a novel variant plasmid content was isolated in Palermo, Italy, in 2014. ST512 is a worldwide successful clone associated with the spread of bla KPC genes located on the IncFIIk pKpQIL plasmid. In our ST512 strain, the bla KPC-3 gene was unusually located on an IncX3 plasmid, whose complete sequence was determined. Two copies of bla KPC-3 ::Tn 4401a caused by intramolecular transposition events were detected in the plasmid.

transposonsequence analysispolymerase chain reactionDrug ResistanceGene DosageSettore MED/42 - Igiene Generale E Applicatabacterial proteinbeta-Lactamaseopen reading framecarbapenemasePlasmidminocyclineplasmid DNAmeropenemPharmacology (medical)geneticscolistincefpodoximeceftazidime610 Medicine & healthCarbapenemBacterialpolymyxin Btimentingene expression regulationbacteriumKlebsiella pneumoniae carbapenemase 3 producing Klebsiella pneumoniae3. Good healthantiinfective agentmicrobial sensitivity testKlebsiella pneumoniaeItalypriority journaltigecyclineMultipleclone (Java method)cefotaxime030106 microbiologyKlebsiella pneumoniae carbapenemase 3tobramycinMicrobial Sensitivity Testsgentamicinpiperacillin plus tazobactamchemistryGene dosageArticleMicrobiology03 medical and health sciencesComplete sequenceClone CellOpen Reading FramesertapenemBacterial Proteinsmultidrug resistanceextensively drug resistant bacteriumAnti-Bacterial AgentcefepimePharmacologylevofloxacinmicrobiologycefoxitinbiochemical phenomena metabolism and nutritionbacterial infections and mycosesVirologyAnti-Bacterial Agents; Bacterial Proteins; Carbapenems; Clone Cells; Drug Resistance Multiple Bacterial; Gene Dosage; Italy; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Open Reading Frames; Plasmids; beta-Lactamases; DNA Transposable Elements; Gene Expression Regulation Bacterial; Pharmacology (medical); Pharmacology; Infectious Diseasesantibiotic sensitivityClone CellsKlebsiella InfectionsceftriaxoneCarbapenemsbacterial genetics0301 basic medicinemolecular cloningSettore MED/07 - Microbiologia E Microbiologia ClinicaKlebsiella pneumoniaeTransposition (music)Drug Resistance Multiple Bacterialpolycyclic compoundsgenetic screeningcell clonecarbapenem derivativeKlebsiella infectionunclassified drugAnti-Bacterial AgentsInfectious Diseasesbacterial genePlasmidsenzymologydoripenemBiologyminimum inhibitory concentrationbeta-Lactamasesbeta lactamaseMechanisms of ResistanceciprofloxacinAmikacin; aztreonam; carbapenemase; cefepime; cefotaxime; cefoxitin; cefpodoxime; ceftazidime; ceftriaxone; ciprofloxacin; colistin; cotrimoxazole; doripenem; doxycycline; ertapenem; gentamicin; imipenem; Klebsiella pneumoniae carbapenemase 3; levofloxacin; meropenem; minocycline; piperacillin plus tazobactam; plasmid DNA; polymyxin B; tigecycline; timentin; tobramycin; unclassified drug; antiinfective agent; bacterial protein; beta lactamase; carbapenem derivative; transposon antibiotic sensitivity; Article; bacterial gene; bacterial genetics; bacterial strain; bacterium; bacterium detection; bacterium isolation; Escherichia coli; extensively drug resistant bacterium; gene dosage; genetic screening; Italy; Klebsiella pneumoniae; Klebsiella pneumoniae carbapenemase 3 producing Klebsiella pneumoniae; minimum inhibitory concentration; molecular cloning; nonhuman; polymerase chain reaction; priority journal; sequence analysis; cell clone; chemistry; drug effects; enzymology; gene expression regulation; genetics; isolation and purification; Klebsiella infection; Klebsiella pneumoniae; metabolism; microbial sensitivity test; microbiology; multidrug resistance; open reading frame; plasmid; transposon Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Clone Cells; DNA Transposable Elements; Drug Resistance Multiple Bacterial; Gene Dosage; Gene Expression Regulation Bacterial; Italy; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Open Reading Frames; Plasmidsplasmidbacterium isolationEscherichia coliGeneAmikacinbacterium detectionnonhumandoxycyclineisolation and purificationGene Expression Regulation Bacterialbiology.organism_classificationbacterial straincotrimoxazoleOpen reading frameDNA Transposable Elementdrug effectsDNA Transposable Elementsmetabolismaztreonamimipenem
researchProduct